Mitoxantrone: its development and role in clinical practice.
Mitoxantrone is an antitumor agent that was synthesized to try to develop a doxorubicinlike drug with a better therapeutic index. It has clinical activity for acute leukemias, breast carcinoma, non-Hodgkin's lymphoma, and ovarian cancers. There is some lack of cross-resistance to the anthracyclines. Its spectrum of toxicity is advantageous in that it causes less alopecia and can be administered for a slightly longer time than doxorubicin. For selected patients, mitoxantrone can be useful as a substitute for doxorubicin, but doxorubicin will remain the more widely used drug.
Weiss
R B
RB
Walter Reed Army Medical Center, Washington, DC.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008942:Mitoxantrone / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy
D008942:Mitoxantrone